Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's ...

More than a third of COVID-19 cases in the U.S. are now estimated to be ... 1 has "good cross-reactivity" for KP.2. While ...

The French drug giant Sanofi is taking a minority stake in Novavax and entering into a licensing agreement worth as much as ...

Controversies surrounding vaccine side-effects persist despite Covid-19 waning. Covishield, developed by AstraZeneca and ...

The deal will allow Novavax to lift its “going concern” warning, which it first issued in 2023 due to having “substantial doubt” about its ability to survive.

which has seen its share price crumble and come under activist investor pressure as it struggles to sell its COVID shot. The company pitched the vaccine as an alternative to the dominant messenger RNA ...

A Sussex County state representative plans to introduce a bill that will hold lawmakers to the same rules its Democrat ...

Moderna’s pioneering COVID shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its ...

The Oxford-AstraZeneca vaccine was a critical part of the COVID-19 pandemic response. However, on May 7, 2024, the European ...

The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects.

Pfizer's stock has experienced significant fluctuations in ... As you know, our business continues to be negatively impacted by a declining COVID environment on a global basis. To that end, we expect ...